An AE was any untoward medical occurrence in a participant who administered a medicinal product without regard to possibility of causal relationship with the study treatment. SAE was defined as one of the following: resulted in death; was life-threatening (immediate risk of death); requires inpatient hospitalization or prolongation of hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); constituted a congenital anomaly/birth defect. Treatment-emergent AE was defined as an AE with onset date occurring during the on-treatment period. AEs included all SAEs and non-SAEs.

TEAEs and SAEs were summarised for only Tafamidis treated set: all available data from participants who have been enrolled in THAOS, signed the informed consent and were on tafamidis treatment on or prior to the date of enrollment of THAOS, or subsequently initiated tafamidis treatment after the enrollment of THAOS.

A treatment-related AE was any untoward medical occurrence attributed to the administered medicinal product in a participant who received study drug. Treatment emergent AEs included both SAEs and all non-SAEs. A treatment-related SAE was a treatment-related AE and was defined as any untoward medical occurrence at any dose that: resulted in death; was life-threatening (immediate risk of death); requires inpatient hospitalization or prolongation of hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); constituted a congenital anomaly/birth defect. Causality was assessed by the investigator.

Treatment emergent treatment related AEs and SAEs were summarised for only tafamidis treated set: all available data from participants who have been enrolled in THAOS, signed the informed consent and were on tafamidis treatment on or prior to the date of enrollment of THAOS, or subsequently initiated tafamidis treatment after the enrollment of THAOS.

Number of deaths due to any cause was analyzed as time from enrollment or first treatment of tafamidis.

Tafamidis treated set included participants who were on tafamidis at or prior to the enrollment, as well as participants who were not on tafamidis at enrollment but subsequently initiated tafamidis treatment during the study. Tafamidis untreated set included participants who were enrolled and never received tafamidis throughout the study, as well as participants who were not on tafamidis before or at enrollment but subsequently initiated tafamidis treatment during the study.

Modified Polyneuropathy Disability (mPND) is a score that categorizes participants into six stages (0, I,II, IIIa, IIIb, IV) based on mobility status. 0 = No sensory disturbances in the feet and able to walk without difficulty; I=Sensory disturbances in the feet but able to walk without difficulty; II=Some difficulties with walking but can walk without aid; IIIa=Able to walk with 1 stick or crutch; IIIb=Able to walk with 2 sticks or crutches; IV=Not ambulatory, confined to a wheelchair or bedridden. Higher stage indicates lower mobility status.

Overall analysis set:all enrolled participants in THAOS study.Tafamidis treated set:participants who were on tafamidis at or prior to the enrollment, as well as those who were not on tafamidis at enrollment but subsequently received tafamidis during the study.Tafamidis untreated set:participants who were enrolled and never received tafamidis throughout the study, as well as those who were not on tafamidis before or at enrollment but subsequently started tafamidis treatment during the study.

Coutinho disease stages is the most common classification used to capture ATTR (Transthyretin Amyloidosis) disease progression. Participants with stage 0 disease are asymptomatic, Participants with stage 1 (mild) disease are ambulatory, Participants with stage 2 (moderate) disease are ambulatory but require assistance and/or have involvement of the upper limbs, and Participants with stage 3 (severe) disease are bedridden or wheelchair-bound.

Overall analysis set:all enrolled participants in THAOS study.Tafamidis treated set:participants who were on tafamidis at or prior to the enrollment, as well as those who were not on tafamidis at enrollment but subsequently received tafamidis during the study.Tafamidis untreated set:participants who were enrolled and never received tafamidis throughout the study, as well as those who were not on tafamidis before or at enrollment but subsequently started tafamidis treatment during the study.

Karnofsky performance score is used to quantify participant's general well-being and activities of daily life and participants are classified based on their functional impairment. Karnofsky performance score is 10 level score which ranges between 10 (moribund) to 100 (normal, no evidence of disease). Higher score means higher ability to perform daily tasks.

Overall analysis set:all enrolled participants in THAOS study.Tafamidis treated set:participants who were on tafamidis at or prior to the enrollment, as well as those who were not on tafamidis at enrollment but subsequently received tafamidis during the study.Tafamidis untreated set:participants who were enrolled and never received tafamidis throughout the study, as well as those who were not on tafamidis before or at enrollment but subsequently started tafamidis treatment during the study.

Heart failure, also known as congestive heart failure is a cardiovascular event.

Overall analysis set:all enrolled participants in THAOS study.Tafamidis treated set:participants who were on tafamidis at or prior to the enrollment, as well as those who were not on tafamidis at enrollment but subsequently received tafamidis during the study.Tafamidis untreated set:participants who were enrolled and never received tafamidis throughout the study, as well as those who were not on tafamidis before or at enrollment but subsequently started tafamidis treatment during the study.

New York Health Association (NYHA) functional classification included: Class I (no limitation in physical activity, no dyspnea with normal activity), Class II (slight limitation of physical activity; fatigue, palpitation, or dyspnea with ordinary physical activity), Class III (marked limitation of physical activity; fatigue, palpitation, or dyspnea with less than ordinary physical activity) and Class IV (cannot perform a physical activity without any symptoms, dyspnea at rest).

Overall analysis set:all enrolled participants in THAOS study.Tafamidis treated set:participants who were on tafamidis at or prior to the enrollment, as well as those who were not on tafamidis at enrollment but subsequently received tafamidis during the study.Tafamidis untreated set:participants who were enrolled and never received tafamidis throughout the study, as well as those who were not on tafamidis before or at enrollment but subsequently started tafamidis treatment during the study.

Participants diagnosed with Transthyretin Amyloidosis (ATTR) at baseline with assessed category of yes, no, and unknown.

Overall analysis set:all enrolled participants in THAOS study.Tafamidis treated set:participants who were on tafamidis at or prior to the enrollment, as well as those who were not on tafamidis at enrollment but subsequently received tafamidis during the study.Tafamidis untreated set:participants who were enrolled and never received tafamidis throughout the study, as well as those who were not on tafamidis before or at enrollment but subsequently started tafamidis treatment during the study.

Number of participants with ATTR and participants who had prior misdiagnosis at the baseline were reported.

Overall analysis set:all enrolled participants in THAOS study.Tafamidis treated set:participants who were on tafamidis at or prior to the enrollment, as well as those who were not on tafamidis at enrollment but subsequently received tafamidis during the study.Tafamidis untreated set:participants who were enrolled and never received tafamidis throughout the study, as well as those who were not on tafamidis before or at enrollment but subsequently started tafamidis treatment during the study.

Genetic mutation leads to misfolding of protein transthyretin (TTR) which results in ATTR. In this outcome, number of participants with ATTRv mutation type and wild type TTR were reported.

Overall analysis set:all enrolled participants in THAOS study.Tafamidis treated set:participants who were on tafamidis at or prior to the enrollment, as well as those who were not on tafamidis at enrollment but subsequently received tafamidis during the study.Tafamidis untreated set:participants who were enrolled and never received tafamidis throughout the study, as well as those who were not on tafamidis before or at enrollment but subsequently started tafamidis treatment during the study.

Number of participants had previous or current participant in any clinical trials at the baseline.

Overall analysis set:all enrolled participants in THAOS study.Tafamidis treated set:participants who were on tafamidis at or prior to the enrollment, as well as those who were not on tafamidis at enrollment but subsequently received tafamidis during the study.Tafamidis untreated set:participants who were enrolled and never received tafamidis throughout the study, as well as those who were not on tafamidis before or at enrollment but subsequently started tafamidis treatment during the study.

Number of participants being allowed for the use of Tafamidis when under strict conditions, Tafamidis was in development and made available to groups of participants who have a disease with no satisfactory authorised therapies and who cannot enter clinical trials.

Overall analysis set:all enrolled participants in THAOS study.Tafamidis treated set:participants who were on tafamidis at or prior to the enrollment, as well as those who were not on tafamidis at enrollment but subsequently received tafamidis during the study.Tafamidis untreated set:participants who were enrolled and never received tafamidis throughout the study, as well as those who were not on tafamidis before or at enrollment but subsequently started tafamidis treatment during the study.

Number of participants whether with family history of symptomatic ATTR amyloidosis at Baseline were reported.

Overall analysis set:all enrolled participants in THAOS study.Tafamidis treated set:participants who were on tafamidis at or prior to the enrollment, as well as those who were not on tafamidis at enrollment but subsequently received tafamidis during the study.Tafamidis untreated set:participants who were enrolled and never received tafamidis throughout the study, as well as those who were not on tafamidis before or at enrollment but subsequently started tafamidis treatment during the study.

The mean of affected generations in participants with a known family history was reported.

Overall analysis set:all enrolled participants in THAOS study.Tafamidis treated set:participants who were on tafamidis at or prior to the enrollment, as well as those who were not on tafamidis at enrollment but subsequently received tafamidis during the study.Tafamidis untreated set:participants who were enrolled and never received tafamidis throughout the study, as well as those who were not on tafamidis before or at enrollment but subsequently started tafamidis treatment during the study.

Neuropathy Impairment Score - Lower Limb (NIS-LL) assessed motor, sensory and reflex activity specifically in the lower limbs and combined total scores for the lower limbs were collected and reported. Derived NIS LL score extends from 0 (normal functions) to a maximum possible value of 88 points, the scale is additive for all deficits and is applied bilaterally for each modality tested: 1) muscle strength: 0 (normal)-4 (paralysis), higher score = more weakness; 2) sensory and 3) reflex testings: 0=normal, 1=decreased, or 2=absent. Reflex score: 0 (normal)-10 (present), higher score =present in more anatomic sites; Motor score: 0-160 (full range of motion with maximum resistance across all anatomical sites), higher score=more impairment. Sensory Score has a range of 0 to the normal value of 124 where ratings are coded as 0=absent; 1=decreased; 2=normal.

Overall analysis set:all enrolled participants in THAOS study.Tafamidis treated set:participants who were on tafamidis at or prior to the enrollment, as well as those who were not on tafamidis at enrollment but subsequently received tafamidis during the study.Tafamidis untreated set:participants who were enrolled and never received tafamidis throughout the study, as well as those who were not on tafamidis before or at enrollment but subsequently started tafamidis treatment during the study.

BMI was calculated by weight divided by height squared and measured as kilogram per square meter (kg/m^2).

Overall analysis set:all enrolled participants in THAOS study.Tafamidis treated set:participants who were on tafamidis at or prior to the enrollment, as well as those who were not on tafamidis at enrollment but subsequently received tafamidis during the study.Tafamidis untreated set:participants who were enrolled and never received tafamidis throughout the study, as well as those who were not on tafamidis before or at enrollment but subsequently started tafamidis treatment during the study.

mBMI was calculated by multiplying BMI by serum albumin levels [gram/liter (g/L)]. mBMI was measured as kg/m^2*g/L. A progressive decline in mBMI indicated worsening of disease severity.

Overall analysis set:all enrolled participants in THAOS study.Tafamidis treated set:participants who were on tafamidis at or prior to the enrollment, as well as those who were not on tafamidis at enrollment but subsequently received tafamidis during the study.Tafamidis untreated set:participants who were enrolled and never received tafamidis throughout the study, as well as those who were not on tafamidis before or at enrollment but subsequently started tafamidis treatment during the study.

BP (Blood Pressure) is the pressure of the blood within the arteries. It is produced primarily by the contraction of the heart muscle. BP measurement is recorded by 2 numbers: systolic BP (SBP, BP when heart is contracting; it is the maximum arterial pressure during contraction of left ventricle) and diastolic BP (DBP, BP when heart is relaxing; it is the minimum arterial pressure during relaxation and dilation of ventricles). Available sitting SBP and DBP at Baseline were reported.

Overall:all available data from enrolled participants.Tafamidis treated:available data from enrolled participants that were on tafamidis at or prior to the enrollment,and those not on tafamidis at the enrollment but later initiated tafamidis.Tafamidis untreated:available data from enrolled participants and did not receive tafamidis throughout and those not on tafamidis prior or at enrollment but later initiated tafamidis.Number analyzed=participants with available BP data collected at baseline.

Cardiac amyloidosis is attributable to intramyocardial amyloid infiltration, which leads to a progressive increase of ventricular wall thickness and stiffness. A left ventricular (LV) wall thickness ≥12 mm plus at least one red flag should raise the suspicion of cardiac amyloidosis.

Overall analysis set: All available data from enrolled participants in THAOS study. Tafamidis treated set: All available data from participants enrolled in THAOS that were on tafamidis at and prior to the enrollment; participant not on tafamidis at the enrollment subsequently initiated treatment. Tafamidis untreated set: All available data from participants enrolled in THAOS and did not receive tafamidis during the study, including those initiated receiving tafamidis post enrollment.

Left ventricular dysfunction, a condition in which the left ventricle of the heart exhibits a decreased functionality, was assessed based on systolic ejection fraction. Systolic ejection fraction was the fraction of the end-diastolic volume (EDV) that was ejected out of left ventricle with each contraction.

Overall analysis set: All available data from enrolled participants in THAOS study. Tafamidis treated set: All available data from participants enrolled in THAOS that were on tafamidis at and prior to the enrollment; participant not on tafamidis at the enrollment subsequently initiated treatment. Tafamidis untreated set: All available data from participants enrolled in THAOS and did not receive tafamidis during the study, including those initiated receiving tafamidis post enrollment.

EQ-5D-3L VAS: participant rated questionnaire to assess generic health status in two parts: single utility score and visual analog scale. The VAS component rated the current health state on a scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicating a better health state.

Overall analysis set: All available data from enrolled participants in THAOS study. Tafamidis treated set: All available data from participants enrolled in THAOS that were on tafamidis at and prior to the enrollment; participant not on tafamidis at the enrollment subsequently initiated treatment. Tafamidis untreated set: All available data from participants enrolled in THAOS and did not receive tafamidis during the study, including those initiated receiving tafamidis post enrollment.

The EQ-5D-3L VAS derived index is calculated by subtracting the values of the descriptive EQ-5D system from the numerical value. This corresponds to the best possible health status, the scale of the Derived Index is 0 [death] to 1 [perfect health]. EQ-5D-3L VAS overall health score and derived score data were sourced from different part of the EQ-5D questionnaire and are conceptually different from each other as EQ VAS is a 0-100 scale and EQ-5D index is a value attached to an EQ-5D profile according to a set of weights that reflect, on average, participant's preferences about how good or bad the state is. More data were collected for EQ-5D index score compared to EQ VAS overall health score at the baseline.

Overall analysis set:all enrolled participants in THAOS study.Tafamidis treated set:participants who were on tafamidis at or prior to the enrollment, as well as those who were not on tafamidis at enrollment but subsequently received tafamidis during the study.Tafamidis untreated set:participants who were enrolled and never received tafamidis throughout the study, as well as those who were not on tafamidis before or at enrollment but subsequently started tafamidis treatment during the study.

Norfolk QOL: 35-item participant-rated questionnaire used to assess impact of neuropathy on the quality of life of participants diagnosed with ATTR. Scoring was based on 35 questions that yield a TQOL as well as 5 subscale scores: activities of daily living, large fiber neuropathy/physical functioning, small fiber neuropathy, autonomic neuropathy, and symptoms. TQOL= sum of all the items, total possible score range= -2 to 138, where higher score=worse quality of life.

Overall analysis set: All available data from enrolled participants in THAOS study. Tafamidis treated set: All available data from participants enrolled in THAOS that were on tafamidis at and prior to the enrollment; participant not on tafamidis at the enrollment subsequently initiated treatment. Tafamidis untreated set: All available data from participants enrolled in THAOS and did not receive tafamidis during the study, including those initiated receiving tafamidis post enrollment.

Following parameters were analyzed: heart rate, PR interval, QT interval, QRS interval and QT interval corrected using Fridericia's formula (QTcF). Abnormal findings in ECG were based on investigator's discretion.

Overall analysis set: All available data from enrolled participants in THAOS study. Tafamidis treated set: All available data from participants enrolled in THAOS that were on tafamidis at and prior to the enrollment; participant not on tafamidis at the enrollment subsequently initiated treatment. Tafamidis untreated set: All available data from participants enrolled in THAOS and did not receive tafamidis during the study, including those initiated receiving tafamidis post enrollment.

Number of participants with atrial fibrillation/flutter (rapid, irregular heart rhythm), implanted artificial cardiac pacemaker, and implantable cardioverter-defibrillator (ICD) (detects and stops irregular heartbeats, also called arrhythmias) were reported.

Overall analysis set: All available data from enrolled participants in THAOS study. Tafamidis treated set: All available data from participants enrolled in THAOS that were on tafamidis at and prior to the enrollment; participant not on tafamidis at the enrollment subsequently initiated treatment. Tafamidis untreated set: All available data from participants enrolled in THAOS and did not receive tafamidis during the study, including those initiated receiving tafamidis post enrollment.